Invite: Expert Access: Barclays Hosted: Expert Call on PKU Treatment Landscape: PTCT's Sephience & BMRN's Palynziq

Research evidence excerpt

Invite: Expert Access: Barclays Hosted: Expert Call on PKU Treatment Landscape: PTCT's Sephience & BMRN's Palynziq

lysosomal storage diseases, fatty acid oxidation defects, PKU, and bone marrow

transplantation for inborn errors in metabolism. Dr. Ficicioglu's research has been

published in the Journal of Inherited Metabolic Disease, the Turkish Journal of Medical &

Biological Research, the Turkish Journal of Pediatrics, Neuropediatrics, the Istanbul Cocuk

Klinigi Dergisi, and Pediatric Neurology. He is the author of a publication on Fabry disease,

has spoken at conferences on topics specific to Fabry disease, and has served as an

investigator on a clinical trial for Fabry disease. He is personally responsible for prescribing

enzyme replacement therapy and substrate reduction therapy to his Fabry disease

patients. Dr. Ficicioglu received his MD from the University of Istanbul Cerrahpasa Medical

School and earned his PhD at the University of Marmara in Turkey. He completed a clinical

fellowship in the Division of Genetics and Metabolism at Harvard Medical School and the

Children's Hospital of Boston.

Meet the Analyst

Eliana Merle, CFA, joined Barclays in November 2025 as an

Equity Research Analyst to cover U.S. Small & Mid Cap

Biotechnology. She has over a decade of sell-side equity

research experience in the sector; most recently, Ellie

worked as a Senior Equity Research Analyst at UBS in

Biotechnology for five years. Prior to that, she also

covered Small & Mid Cap Biotechnology at Cantor

Fitzgerald and held positions at Credit Suisse and

Deutsche Bank in Biotechnology Equity Research. Ellie

graduated from Pomona College with a degree in

Economics.

View Analyst Page

U.S. Small & Mid Cap Biotechnology

Eliana Merle, CFA Jasmine Fels, PhD

+1 212 526 9445 +1 212 526 0865